Nonsteroidal and steroidal aromatase inhibitors in breast cancer

被引：0
|
作者：
Hamilton, A [1 ]
Volm, M [1 ]
机构：
[1] NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA
来源：
ONCOLOGY-NEW YORK | 2001年 / 15卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen (Nolvadex) as the hormonal therapy of choice in estrogen-receptor-positive,postmenopausal, metastatic breast cancer. This article will review the role of aromatase in the pathogenesis of breast cancer and the results of recent studies that have established the role of its inhibitors in estrogen-receptor-positive breast cancer. We will also briefly outline the rationale and design of ongoing studies.
引用
收藏
页码：965 / 972
页数：8
相关论文
共 50 条
  • [1] Nonsteroidal and steroidal aromatase inhibitors in breast cancer - The Hamilton/Volm article reviewed
    Buzdar, AU
    ONCOLOGY-NEW YORK, 2001, 15 (08): : 978 - 979
  • [2] Development of steroidal and nonsteroidal inhibitors of aromatase for the treatment of hormone-dependent breast cancer
    OReilly, JM
    Brueggemeier, RW
    CURRENT MEDICINAL CHEMISTRY, 1996, 3 (01) : 11 - 22
  • [3] Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer
    Ahmad, Irshad
    Shagufta
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 102 : 375 - 386
  • [4] PRETRANSLATIONAL AND POSTTRANSLATIONAL REGULATION OF AROMATASE BY STEROIDAL AND NONSTEROIDAL AROMATASE INHIBITORS
    FOIDART, A
    TLEMCANI, O
    HARADA, N
    ABEDOHMAE, S
    BALTHAZART, J
    BRAIN RESEARCH, 1995, 701 (1-2) : 267 - 278
  • [5] Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
    Miller, William R.
    Bartlett, John
    Brodie, Angela M. H.
    Brueggemeier, Robert W.
    Di Salle, Enrico
    Lonning, Per Eystein
    Llombart, Antonio
    Maass, Nicolai
    Maudelonde, Thierry
    Sasano, Hironobu
    Goss, Paul E.
    ONCOLOGIST, 2008, 13 (08): : 829 - 837
  • [6] Nonsteroidal Aromatase Inhibitors for the Treatment of Breast Cancer: An Update
    Gobbi, Silvia
    Rampa, Angela
    Belluti, Federica
    Bisi, Alessandra
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (01) : 54 - 65
  • [7] Interactions of steroidal and nonsteroidal inhibitors with human aromatase.
    Kao, YC
    Cam, LL
    Laughton, CA
    Zhou, D
    Chen, S
    FASEB JOURNAL, 1996, 10 (06): : 2892 - 2892
  • [8] Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
    Chen, Shanshan
    Bo, Lan
    Lv, Dan
    Ma, Fei
    BREAST CARE, 2022, 17 (04) : 391 - 402
  • [9] Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study
    Wang, Xue
    Zhu, Anjie
    Wang, Jiayu
    Ma, Fei
    Liu, Jing
    Fan, Ying
    Luo, Yang
    Zhang, Pin
    Li, Qing
    Xu, Binghe
    Yuan, Peng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [10] Predictors of effectiveness of the use of steroidal aromatase inhibitors after progression on non-steroidal aromatase inhibitors in advanced breast cancer patients
    Ulrich de Menezes Pereira dos Santos, M. M.
    Cardoso, C.
    Sousa, M.
    Esteves, S.
    Brito, M.
    Moreira, A.
    ANNALS OF ONCOLOGY, 2016, 27
12345